Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Inhibitors & Agonists > Nuclear Receptor/Transcription Factor > Keap1-Nrf2

Keap1-Nrf2

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC40751 CBR-470-2
CBR-470-2, a glycine-substituted analog, and can activate NRF2 signaling. CBR-470-2 can be used for modulation glycolysis.
More description
DC40359 Keap1-Nrf2-IN-1
Keap1-Nrf2-IN-1 (compound35) is a Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction inhibitor, and with an IC50 of 43 nM for Keap1 protein. Keap1-Nrf2-IN-1 activates Nrf2-regulated cytoprotective response and antagonizes acetaminophen-induced liver injury both in cellular and in vivo models.
More description
DC28729 Ezetimibe ketone
Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. Ezetimibe is a potent cholesterol absorption inhibitor.
More description
DC28273 ML334
ML334 is a potent, cell permeable activator of NRF2 by inhibition of Keap1-NRF2 protein-protein interaction. ML334 binds to Keap1 Kelch domain with a Kd of 1 μM. ML334 stimulates NRF2 expression and nuclear translocation and induces antioxidant response elements (ARE) activity.
More description
DC10913 Brusatol
Brusatol (NSC 172924, (+)-Brusatol) is a quassinoid extracted from Brucea Esters, can inhibit HIF-1 signaling pathway, also is a potent Nrf2 inhibitor.
More description
DC11499 BPK-29
BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
More description
DCL-047 Sulforaphane
>98%,Standard References
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X